Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that EGFR Exon 20 (Insertion) status confers therapeutic sensitivity to Amivantamab, Carboplatin, Pemetrexed in patients with Non-Small Cell Lung Cancer.
The European Medicines Agency (EMA) has authorized amivantamab in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating EGFR Exon 20 insertion mutations.
This statement is based on a regulatory approval from the European Medicines Agency:
Rybrevant is indicated in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating EGFR Exon 20 insertion mutations.